DFL23693

DFL23693 is an investigational small molecule dual antagonist of the C-X-C chemokine receptors CXCR1 and CXCR2, developed by Dompe' Farmaceutici. The drug is designed to address the inflammatory and nociceptive components of osteoarthritis by inhibiting the signaling pathways activated by CXCL8 (interleukin-8) and other related chemokines. These pathways are known to play a significant role in the recruitment of neutrophils and the sensitization of pain fibers within the joint environment. DFL23693 is currently undergoing Phase 1 clinical evaluation in healthy volunteers to assess its safety, tolerability, and pharmacokinetics, with the ultimate goal of providing a new therapeutic option for patients suffering from osteoarthritis-related pain and inflammation.